Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Targeted deep sequencing of myeloma in a multi-institutional clinical workflow

Blood (2025) 146 (Supplement 1): 4026.

https://doi.org/10.1182/blood-2025-4026

Published: 2025

Journal Articles

Profile of NDMM patients who remain progression free at 10 years treated with RVD induction and risk adapted maintenance

Om Raval, Lilly Gu, Nisha Joseph, Craig Hofmeister, Vikas Gupta, Richa Parikh, Nishi Shah, Sagar Lonial, Ajay Nooka, Jonathan Kaufman

Blood (2025) 146 (Supplement 1): 2812.

https://doi.org/10.1182/blood-2025-2812

Published: 2025

Journal Articles

Talquetamab bridging therapy for B-cell maturation antigen chimeric antigen receptor T-cell in Relapsed/Refractory multiple myeloma

Sara Scott, Ajay Nooka, Jonathan Kaufman, Craig Hofmeister, Vikas Gupta, Richa Parikh, Nishi Shah, Sagar Lonial, Nisha Joseph

Blood (2025) 146 (Supplement 1): 2811.

https://doi.org/10.1182/blood-2025-2811

Published: 2025

Journal Articles

Final Results of randomized Phase II study of daratumumab, ixazomib, and dexamethasone (DId, ARM A) vs daratumumab, bortezomib and dexamethasone (DVd) followed by daratumumab, did (Arm B) in newly diagnosed multiple myeloma (DeRIVE) study

Ajay Nooka, Nisha Joseph, Madhav Dhodapkar, Vikas Gupta, Craig Hofmeister, Manali Rupji, Bryan Burton, Hafsa Ahmed, Darrian Linton, Stephen Noga, Thomas Lin, Lawrence Boise, Jonathan Kaufman, Sagar Lonial

Blood (2025) 146 (Supplement 1): 5843.

https://doi.org/10.1182/blood-2025-5843

Published: 2025

Journal Articles

Characterizing a racially diverse cohort of patients with AL amyloidosis treated with dara-VCD

Dominique Mosley, Richa Parikh, Sara Scott, Nisha Joseph, Craig Hofmeister, Vikas Gupta, Nishi Shah, Sagar Lonial, Ajay Nooka, Jonathan Kaufman

Blood (2025) 146 (Supplement 1): 3968.

https://doi.org/10.1182/blood-2025-3968

Published: 2025

Journal Articles

Real world evidence comparing idecabtagene vicleucel (Ide-cel, Abecma) versus ciltacabtagene autoleucel (Cilta-cel, Carvykti) chimeric antigen receptor T-cell (CART) therapy among patients with Relapsed/Refractory multiple myeloma (RRMM)

Nisha Joseph, Richa Parikh, Shree Allada, Vikas Gupta, Craig Hofmeister, Nishi Shah, Jonathan Kaufman, Sagar Lonial, Ajay Nooka

Blood (2025) 146 (Supplement 1): 2301.

https://doi.org/10.1182/blood-2025-2301

Published: 2025

Journal Articles

Characterization of NDMM patients treated with daratumumab, lenalidomide, bortezomib and dexamethasone who fail to achieve a VGPR or have early progression

Jonathan Kaufman, Efstathios Kastritis, Nisha Joseph, Maria Gavriatopoulou, Lilly Gu, Craig Hofmeister, Vikas Gupta, Evangelos Terpos, Ajay Nooka, Sagar Lonial, Meletios Dimopoulos

Blood (2025) 146 (Supplement 1): 407.

https://doi.org/10.1182/blood-2025-407

Published: 2025

Journal Articles

A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005)

Paul G. Richardson, MD, Craig Hofmeister, Noopur S. Raje, MD, David Siegel, MD PhD, Sagar Lonial, MD, Jacob P. Laubach, Yvonne A Efebera, MD, David H. Vesole, MD, Ajay K Nooka, Jacalyn Rosenblatt, Mohamed H Zaki, Jennifer Herring, Yan Li, PhD, Sheetal Shah, Min S Chen, Kenneth C Anderson

Blood (2015) 126 (23): 3036.

https://doi.org/10.1182/blood.V126.23.3036.3036

Published: 2015

Journal Articles

Comparison of Two Doses of Antithymocyte Globulin (ATG) in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT)

Hassan Issa, MD, Amy S. Ruppert, MAS, Patrick Elder, M.S, Craig Hofmeister, Don M Benson, MD PhD, Sam Penza, MD, Leslie A. Andritsos, MD, Rebecca B. Klisovic, MD, Sumithira Vasu, MBBS, William Blum, MD, Samantha M. Jaglowski, MD, Steven M. Devine, MD, Yvonne A Efebera, MD

Blood (2015) 126 (23): 4328.

https://doi.org/10.1182/blood.V126.23.4328.4328

Published: 2015

Journal Articles

First Interim Results of a Phase I/II Study of Lenalidomide in Combination with Anti-PD-1 Monoclonal Antibody MDV9300 (CT-011) in Patients with Relapsed/Refractory Multiple Myeloma

Yvonne A. Efebera, MD MPH, Ashley E Rosko, MD, Craig Hofmeister, Joe Benner, BS, Courtney Bakan, BS, Kathleen Stamper, BS, Tammy Lamb, CNP, Devine Hollie, CNP, Megan Sell, CNP, David Avigan, MD, Don M Benson, MD PhD

Blood (2015) 126 (23): 1838.

https://doi.org/10.1182/blood.V126.23.1838.1838

Published: 2015

Journal Articles

p53-Inducible Micrornas 192 and 215 Regulate p53 Expression and IGF1 Axis in Multiple Myeloma.

Flavia Pichiorri, PhD, MSC, Sung-Suk Suh, Luciana De Luca, Cristian Taccioli, Don Benson, MD, PhD, Craig Hofmeister, MD, Rami Aqeilan, Carlo M. Croce, MD

Blood (2009) 114 (22): 1973.

https://doi.org/10.1182/blood.V114.22.1973.1973

Published: 2009

Journal Articles

Phase III Intergroup Study of Lenalidomide (CC-5013) Versus Placebo Maintenance Therapy Following Single Autologous Stem Cell Transplant for Multiple Myeloma (CALGB 100104): Initial Report of Patient Accrual and Adverse Events.

Philip L. McCarthy, MD, Kouros Owzar, PhD, Edward A. Stadtmauer, MD, Sergio Giralt, MD, David D Hurd, MD, Hani Hassoun, MD, Craig Hofmeister, MD, Paul Richardson, M.D., Ph.D., Daniel J. Weisdorf, Marcelo C. Pasquini, MD, Vera Hars, PhD, Michael Kelly, B.S., John Postiglione, Susan Sutherland, Kenneth C. Anderson, MD, Charles Linker, MD

Blood (2009) 114 (22): 3416.

https://doi.org/10.1182/blood.V114.22.3416.3416

Published: 2009

Journal Articles

IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody, and Lenalidomide Combine to Enhance the Natural Killer (NK) Cell Versus Multiple Myeloma (MM) Effect.

Don Benson, MD, PhD, Courtney E Bakan, Shuhong Zhang, PhD, Lana Alghothani, Jing Liang, Craig Hofmeister, MD, Shivani Srivastava, MD, Megan K Smith, MS, CNP, RN, Carli N Greenfield, Pascale Andre, PhD, Patrick Squiban, MD, Francois Romagne, PhD, Michael A. Caligiuri, M.D., Sherif Farag, MBBS, PhD

Blood (2009) 114 (22): 3870.

https://doi.org/10.1182/blood.V114.22.3870.3870

Published: 2009

Journal Articles

Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM).

Paul Richardson, M.D, Craig Hofmeister, MD, Andrzej Jakubowiak, MD, PhD, Todd M. Zimmerman, MD, Matthew A. Spear, MD, Michael A. Palladino, PhD, Angie M. Longenecker, RN, BSN, Susan L. Kelly, MD, Saskia Neuteboom, PhD, Gillian F Cropp, MSc, G. Kenneth Lloyd, PhD, Alison L. Hannah, MD, Kenneth C. Anderson, MD

Blood (2009) 114 (22): 431.

https://doi.org/10.1182/blood.V114.22.431.431

Published: 2009

Journal Articles

Induced Resistance to Bortezomib in Preclinical Model of Waldenstrom Macroglobulinemia Is Associated with Bcl-2 Upregulation.

Kasyapa Chitta, Ph.D., Jean-Gabriel Coignet, Sakina Sojar, Pushpankur Ghoshal, PhD, Kiersten M. Miles, Leighton Stein, Morton Coleman, MD, Richard R. Furman, MD, Craig Hofmeister, MD, Suzanne Hayman, MD, Kelvin P. Lee, MD, Asher A. Chanan-Khan, MD

Blood (2009) 114 (22): 4919.

https://doi.org/10.1182/blood.V114.22.4919.4919

Published: 2009

Journal Articles

Hospital Care of Pathological Vertebral Fracture (PVF) in Multiple Myeloma (MM) Patients: Burden of Illness and Patterns of Care

Jeffrey Alan Jones, MD, MPH, John C. Byrd, MD, Joseph M Flynn, DO, MPH, Craig Hofmeister, MD

Blood (2008) 112 (11): 2409.

https://doi.org/10.1182/blood.V112.11.2409.2409

Published: 2008

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Targeted deep sequencing of myeloma in a multi-institutional clinical workflow

Profile of NDMM patients who remain progression free at 10 years treated with RVD induction and risk adapted maintenance

Talquetamab bridging therapy for B-cell maturation antigen chimeric antigen receptor T-cell in Relapsed/Refractory multiple myeloma

Final Results of randomized Phase II study of daratumumab, ixazomib, and dexamethasone (DId, ARM A) vs daratumumab, bortezomib and dexamethasone (DVd) followed by daratumumab, did (Arm B) in newly diagnosed multiple myeloma (DeRIVE) study

Characterizing a racially diverse cohort of patients with AL amyloidosis treated with dara-VCD

Real world evidence comparing idecabtagene vicleucel (Ide-cel, Abecma) versus ciltacabtagene autoleucel (Cilta-cel, Carvykti) chimeric antigen receptor T-cell (CART) therapy among patients with Relapsed/Refractory multiple myeloma (RRMM)

Characterization of NDMM patients treated with daratumumab, lenalidomide, bortezomib and dexamethasone who fail to achieve a VGPR or have early progression

A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005)

Comparison of Two Doses of Antithymocyte Globulin (ATG) in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT)

First Interim Results of a Phase I/II Study of Lenalidomide in Combination with Anti-PD-1 Monoclonal Antibody MDV9300 (CT-011) in Patients with Relapsed/Refractory Multiple Myeloma

p53-Inducible Micrornas 192 and 215 Regulate p53 Expression and IGF1 Axis in Multiple Myeloma.

Phase III Intergroup Study of Lenalidomide (CC-5013) Versus Placebo Maintenance Therapy Following Single Autologous Stem Cell Transplant for Multiple Myeloma (CALGB 100104): Initial Report of Patient Accrual and Adverse Events.

IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody, and Lenalidomide Combine to Enhance the Natural Killer (NK) Cell Versus Multiple Myeloma (MM) Effect.

Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM).

Induced Resistance to Bortezomib in Preclinical Model of Waldenstrom Macroglobulinemia Is Associated with Bcl-2 Upregulation.

Hospital Care of Pathological Vertebral Fracture (PVF) in Multiple Myeloma (MM) Patients: Burden of Illness and Patterns of Care

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only